New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:55 EDTBEAV, BEAV, CRS, CRS, ANTH, ANTH, EGL, EGL, CVU, CVU, MOG.A, MOG.A, ICFI, ICFI, CYT, CYT, SAIC, SAIC, KEYW, KEYWCowen to host a conference
35th Annual Aerospace/Defense Conference is being held in New York on February 5-6 with webcasted company presentations to begin on February 5 at 9 am. Webcast Link
News For A;CVU;EGL;ANTH;CRS;KEYW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
May 14, 2015
07:43 EDTCVUB. Riley to hold a conference
Subscribe for More Information
May 13, 2015
10:01 EDTEGLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:57 EDTKEYWKEYW management to meet with Maxim
Subscribe for More Information
09:57 EDTKEYWKEYW management to meet with FBR Capital
Subscribe for More Information
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
06:42 EDTEGLEngility upgraded to Buy at Stifel
As previously reported, Stifel upgraded Engility to Buy from Hold with a $31 price target. The firm upgraded shares based on valuation, the improvement in government budgets, low cost structure, and expanded capabilities.
May 12, 2015
10:01 EDTANTHOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:20 EDTANTHOn The Fly: Pre-market Movers
Subscribe for More Information
06:31 EDTANTHAnthera upgraded to Neutral from Sell at Citigroup
Subscribe for More Information
May 11, 2015
17:32 EDTANTHAnthera reports Q1 EPS (28c), consensus (31c)
Reports Q1 revenue $245,000.
16:35 EDTEGLEngility backs FY15 adjusted EPS $1.70-$2.20, consensus $1.84
Subscribe for More Information
16:34 EDTEGLEngility reports funded backlog $938M at Q1-end
Subscribe for More Information
16:33 EDTEGLEngility reports Q1 adjusted EPS 40c, consensus 36c
Reports Q1 revenue $403M, consensus $417.64M.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use